Objective: To examine the metabolic effects and body composition changes after topiramate treatment of obese type 2 diabetic patients (DM2) for 11 months. Design and subjects: Thirty-eight DM2 on diet or sulfonylurea treatment participated in this randomized double-blind placebocontrolled trial. Thirteen placebo-treated and nine topiramate-treated patients completed the trial. Patients were randomized to treatment with topiramate 96 mg b.i.d. or placebo (6-week run-in phase, 2-months titration phase, 9-months maintenance phase). Measurements: Insulin sensitivity was measured with euglycaemic hyperinsulinemic clamps. Weight, HbA1c, fasting glucose, blood lipids and safety variables were measured at regular intervals. Body composition was determined with computerized tomography. Meal tests were performed to evaluate postprandial glucose and insulin levels. Three-day diet recalls were carried out to evaluate energy ingestion. Results: The mean age was 58.677.1 years, body weight 98.1716.1 kg, BMI 33.074.5 kg/m 2 , and glycosylated hemoglobin (HbA1c) 7.370.9%. In topiramate-treated patients, there were significant reductions in HbA1c (1.170.9%), fasting plasma glucose, body weight (À6.673.3%), as well as body fat, lean body mass, postprandial glucose and free fatty acid levels but there were no significant changes in insulin sensitivity. The daily average energy intake decreased more in the topiramate group than in the placebo group. Paresthesia and central nervous system-related side effects were the main causes for the dropout rate. Conclusions: Topiramate treatment of overweight DM2 reduced body weight and body fat, and was associated with a marked improvement in glycaemic control whereas no significant improvement in insulin-stimulated glucose uptake was demonstrated. Further studies are required to clarify whether this effect might occur through changes in insulin sensitivity in the liver and/or pancreatic insulin secretion.
Introduction
There are strong associations between obesity, sedentary lifestyles and diabetes, largely explaining the epidemic spreading of type 2 diabetes (DM2) in many countries during the last decades. Lifestyle changes, including weight reduction, are indispensable in the treatment of patients at risk for DM2, 1 but are also essential adjuncts to pharmacological treatment once the disease has developed. Today, metformin is frequently used as the basis for treatment when oral hypoglycaemic agents are required in obese DM2 individuals, as metformin tends to prevent the increase in body weight commonly seen when glucose control improves. 2 Currently, the only weight-lowering agents approved for long-term use in obese DM2 patients, which have demonstrated beneficial effects in glycemic control, are orlistat, and sibutramine, although these agents have their limitations both in terms of efficacy and patient acceptance. 3 Clearly, more and better agents are needed for the treatment of the obese diabetic patient.
Topiramate is approved for marketing worldwide as an adjunctive anti-seizure therapy in patients with partial onset seizures, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome, and the prophylaxis of migraine headaches. However, recent reports have shown that overweight non-diabetic patients experience significant weight reduction on topiramate treatment. [4] [5] [6] [7] Interestingly, recent studies in animal models of obesity and diabetes have shown that insulin sensitivity is improved by topiramate even before the weight reduction. 8 The mechanism(s) for this is unclear, but recent studies suggested that the adipose tissue might be the target for such an effect in the animal models. 8, 9 It was shown that topiramate improved insulin action and glucose transport in adipose cells from obese and insulin-resistant rodents 8 as well as increased the adiponectin secretion in differentiated 3T3-L1 cells. 9 The aim of the current exploratory study was to examine the metabolic effects, including glycemic control, insulin sensitivity, postprandial glycaemia and lipaemia, as well as body composition changes, after topiramate treatment of obese DM2 patients for 11 months. In addition, we examined if topiramate exerted any direct effects on human adipose tissue in vitro, like in the animal models. 8 
Methods

Patients
The Ethics Committee of Göteborg University and the Swedish Medical Products Agency approved this investigator-initiated study, which was performed according to the Declaration of Helsinki and the principles of ICH Good Clinical Practice. Non-smoking men aged 35-75 years and postmenopausal women aged 45-75 years, who had DM2 for at least 6 months before enrolment, were recruited via newspaper advertisements. Diagnosis of DM2 was established by no history of ketoacidosis, no urine ketone 2 þ or more on urine dipstick, and with a maintained endogenous C-peptide production defined as X0.5 mg/l 15 min following 1 mg of glucagon injected intravenously. Glycosylated hemoglobin (HbA1c) was required to be 6.5-10% and body mass index (BMI) 27-50 kg/m 2 . Patients should be weightstable (74 kg for 2 months) and their diabetes controlled either by diet alone or by a stable dose of a sulfonylurea (SU) in monotherapy for a minimum of 6 months. The study, initiated in May 2000 and completed in May 2002, included a 6-weeks screening phase, an 8-weeks double-blind titration phase and a 9-months double-blind maintenance phase. Topiramate was dosed as 192 mg/day (96 mg b.i.d.). After the maintenance phase, topiramate was tapered over 2 weeks and subjects were followed up a further 4 weeks off-drug, concluded by a final visit.
The number of patients to be evaluated in this hypothesisgenerating exploratory study was not based on formal statistical reasoning. Thirty-eight subjects were enrolled and completed the screening phase and were randomly assigned to receive placebo (N ¼ 19) or topiramate (N ¼ 19) where six and five patients, respectively, were treated with SU. Thirteen of the placebo-treated and nine of the topiramate-treated patients completed the trial. The causes for discontinuation, which generally occurred during the titration phase and first half of the maintanence phase, were premature termination of the study by the sponsor (placebo two, topiramate one), subject choice (placebo two, topiramate one), other (placebo one) and adverse events (placebo one, topiramate eight).
During the double-blind phase, the SU dose remained unchanged in all the topiramate-treated patients. In the placebo-treated group (six SU-treated), the dose of glimeperide was reduced in one patient whereas the dose of glibenclamide was increased in two patients. Among the patients participating the full double-blind period, 11 subjects were treated with antihypertensive drugs (including four topiramate-treated subjects), and one placebo-treated patient used a statin for hyperlipidaemia. The participants were instructed not to start a diet or an exercise programme intended to induce weight loss during the course of the study.
Glucose clamp
The primary efficacy variable was change in insulin sensitivity (as measured with the euglycemic hyperinsulinemic clamp). The euglycemic clamps were conducted essentially as reported by DeFronzo. 10 The steady-state insulin infusion rate was 1 mU/kg/min and the blood glucose was clamped at 5.0 mmol/l. The steady-state insulin concentrations were approximately 95 mU/ml and not significantly different between the groups. (3-3 H) glucose was infused for 120 min before the clamp to measure rate of hepatic glucose production (rate of appearance, R a ) and glucose disposal (rate of disappearance, R d ), as described previously using the HOT GINF technique. 11, 12 The glucose infusion rate was related to the lean body mass (LBM) estimated by computerized tomography (CT).
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Body composition Secondary efficacy variables included mean change in bodyweight, body composition and visceral and subcutaneous abdominal adipose tissue areas. The method for determination of adipose tissue volumes is based on tomographic scans and has previously been described in detail by Sjöström et al. 14 Briefly, the subjects were examined in supine position. A radiograph of the skeleton was used as the reference to establish the position of the scan at lumbar vertebrae L4-L5. Adipose tissue areas were calculated by delineating the areas with a graph pen, and then computing the adipose surfaces using an attenuation range of À190 to À30 HU for adipose tissue. 14 LBM was calculated as the difference between total body weight and 0.923 Â (total Topiramate in type 2 diabetes B Eliasson et al adipose tissue volume) as described previously in detail. 13 Sagittal diameter at the L4-L5 levels was also obtained from these results.
Other measurements HbA1c, fasting plasma glucose (FPG), blood lipid profile and circulating cytokine levels were also measured regularly. A standardized meal test (energy content 900 kcal/3.75 MJ; 51 g of fat) was performed as described before, 15 and glucose, insulin and blood triglyceride levels were followed for 8 h every 2 h. Safety evaluations (reporting of adverse events, physical examination, retinal photography, blood pressure, electrocardiogram, and clinical routine laboratory tests) were performed at regular intervals during the study. Selfmonitored blood glucose measurements (SMBG) were carried out during the titration period in order to avoid hypoglycaemia. Three-day food diaries of the quantity and types of food consumed immediately preceding the scheduled visits were also collected. All laboratory measurements were taken after an 8 h overnight fast and analysed by an accredited central laboratory (COVANCE Labs, Geneva, Switzerland). All efficacy variables, including the clamps, the meal tests and body composition measurements, were examined within a 2-week window at baseline and after treatment with topiramate or placebo for 11 months.
Studies of adipose tissue in vitro
Biopsies of the subcutaneous adipose tissue were obtained from five individuals undergoing abdominal surgery for an isolated disorder, usually a non-malignant gynecological disorder or laparoscopic surgery. In addition, subcutaneous abdominal adipose tissue was obtained by a needle-biopsy procedure from five obese and DM2 subjects. These samples were used to study basal and insulin-stimulated glucose transport in isolated subcutaneous fat cells using ( 14 C-U) glucose as reported previously. 16 Glycerol was measured as an index of lipolysis in the basal state and following the addition of 4mM 8-bromo cAMP. Explants of human abdominal subcutaneous adipose tissue from non-diabetic individuals were cultured for 24 h with or without 100 mM topiramate as described previously. 17 Following RNA extraction, mRNA levels were measured for the indicated genes using real-time polymerase chain reaction (Taqman) and 18S as gene of reference. Primers and probes used are available on request.
Statistical analyses
As this was an exploratory study there was no formal hypothesis testing. Comparisons between means were performed with Student's t-test for unpaired samples, and between proportions using the w 2 test. Multivariate analyses were performed to adjust for age and gender, with change of a variable as independent variables and with age, sex and treatment (topiramate or placebo) as dependent variables.
Only subjects who completed the 11-month treatment period were included in the calculations. Significance levels were adjusted for age and gender. A P-value o0.05 was considered statistically significant. All statistical analyses were performed by JMP (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
The demographic and baseline characteristics of the randomized patients by treatment are summarized in Table 1 . In general, the two groups were similar at inclusion both with regard to anthropometric and metabolic variables. However, the topiramate group tended to have higher baseline fasting glucose and HbA1c levels. The patients who subsequently discontinued had statistically significantly lower BMI at baseline than the other randomized patients (31.072.7 vs 34.475.0 kg/m 2 , P ¼ 0.02). The mean weight, waist circumference and diastolic blood pressure values of this group was also slightly lower (P-values o0.05), whereas all other demographic and baseline characteristics were similar compared with the other randomized patients (data not shown).
Safety
There were no significant differences between the two groups in changes in blood pressure (À9/À5 mm Hg in the topiramate group, À5/À3 mm Hg in the placebo group). There were no clinically significant changes in safety laboratory values, except a slight increase in chloride (mean 3.3 mmol/l) in the topiramate group, which probably is a compensatory effect of the known carbonic anhydrase inhibitory effect of topiramate. The most common central nervous system (CNS)-related adverse events that occurred more frequently in topiramate-treated than in placebotreated patients were paresthesia (15 vs four patients), headache (six vs four), fatigue (six vs four), dizziness (three vs two), anorexia (three vs zero), depression (two vs one), difficulty with concentration/attention (two vs zero), insomnia (two vs one), and nervousness (two vs zero). Other common treatment-emergent adverse events that were not CNS-related and were reported more often in the topiramate group were nausea (three vs one), gastritis (two vs zero), dry mouth (two vs zero), tooth caries (two vs zero) and muscle weakness (two vs zero). Serious adverse events occurred in three topiramate-treated patients (atrial fibrillation, pulmonary hamartoma and a malignant breast neoplasm). All of these were classified by the investigators as not related to the study treatment. More topiramate-treated patients than placebo-treated patients discontinued owing to an adverse event (eight patients, vs one patient).
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Treatment effects
The mean decrease in HbA1c in topiramate-treated patients was 1.170.9%, whereas the placebo group increased by 0.370.8% (Table 2 ). This marked reduction in HbA1c levels in topiramate-treated patients was also associated with lower fasting glucose levels (mean decrease 1.371.1 mmol/l) as well as lower SMBG; mean decrease 1.871.9 mmol/l; Table 2 . There was no significant difference in change of insulin sensitivity (Rd) measured during the clamps between the two groups (topiramate 0.9472.30 and placebo 0.7071.07 mg/kg LBM Â min; P ¼ 0.7; intention to treat analysis). Similarly, there were no significant differences between the two groups regarding absolute peripheral glucose disposal rate or effect on hepatic glucose output (HGO) ( Table 2) . However, the relative inhibition in HGO during the hyperinsulinemia was greater in the topiramate group (56 vs 13% reduction with topiramate and placebo, respectively), but this effect did not reach statistical significance (P ¼ 0.4). ). In the topiramate-treated patients, the mean reductions in subcutaneous and total abdominal adipose tissue areas were 13.0 and 14.0%, respectively (Table 3 ). In the placebo-treated patients subcutaneous and total abdominal adipose tissue areas were virtually unchanged À1.9 and À2.2% (comparison with topiramate-treated patients Po0.01). Similarly, the decrease in visceral abdominal adipose tissue area in the topiramate-treated group was 17.2% and in the placebotreated patients À0.9% (Po0.05). In the topiramate-treated group, the mean decreases in total body fat mass and mean LBM were 5.673.0 and 1.571.6 kg, respectively, whereas only minimal changes were seen in the placebo-treated group (Table 3) .
Lipids, meal tests and dietary recall
Fasting lipid changes are shown in Table 4 . The mean changes in lipid values were modest and not statistically significantly different between the two groups. During the meal tests (Table 4 ; complete data from seven and 11 topiramate-and placebo-treated patients, respectively), there were significant differences between the topiramate and the placebo groups in changes of area under curves for plasma glucose (À13.4723.5 vs 4.20711.9, Po0.05) and free fatty acids (À0.88 þ 0.43 vs 0.34 þ 0.35; Po0.05), but non-significant changes of area under curves for serum insulin (À80.4781.2 vs -23.5762.9) and triglycerides (À3.82710.3 vs -2.4676.11).
The 3-day diet recall (n ¼ 21) showed that the daily average energy intake decreased more in the topiramate group than in the placebo group (À2957306 kcal, À1.2471.28 MJ vs þ 6.427339 kcal, 0.03071.43 MJ; Po0.05).
Cytokines
There were no significant differences of changes during the 9-month treatment period between the two groups regarding interleukin (IL)-6 and IL-8, adiponectin, tumour-necrosis factor (TNF)-a, resistin or CRP (n ¼ 14, Table 5 ).
Correlations
In the overall group, the weight reduction during the study correlated not only with the change of energy intake (r ¼ 0.59, P ¼ 0.045), but also with reductions in HbA1c Effect of topiramate in human adipose cells in vitro As rodent and murine adipose cells appear to be target cells for topiramate, 8, 9 we also examined if topiramate exerted any direct effects in human fat cells in vitro. However, no direct effects on glucose uptake or enhancement of the insulin-stimulated effect was seen in fat cells from lean, Topiramate in type 2 diabetes B Eliasson et al obese or DM2 subjects (data not shown). We also cultured explants of human adipose tissue for 24 h with topiramate (100 mM) and examined gene expression of adiponectin, aP2, GLUT-4 and IRS-1, but no effect was found (data not shown). Finally, we examined if topiramate exerted any effects on lipolysis (basal and cAMP-stimulated) or the anti-lipolytic effect of insulin. However, no effect of topiramate on any of these processes was found (data not shown).
Discussion
The main result of this study is that treatment with topiramate for 11 months added to SU or diet alone in overweight DM2 patients significantly reduces body weight and markedly improves glycemic control even in the absence of any significant changes in inflammatory markers (CRP, cytokines) or adiponectin. The mean weight reduction in Table 4 Metabolic variables following a standardized meal test before and after the 11-month treatment period Abbreviation: FFA, free fatty acid. Mean values7s.d. There were no significant differences at baseline between the two groups. P-value denotes the treatment effect (difference between the changes in the two groups). Insulin/glucose; serum insulin/plasma glucose concentrations ratio (mU/ml/mmol/l). Whole-body insulin sensitivity was unchanged in spite of the favourable effects of topiramate on weight and glycaemia. This lack of effect is also consistent with the unchanged adiponectin levels as close correlations between adipokine and insulin sensitivity have repeatedly been shown. 18 Interestingly, there were also no significant changes in fasting blood lipids or blood pressure, although there was a trend towards improvement. The high dropout rate during this study was mainly caused by paresthesia and other CNS-related side effects. The 3-day diet recall data showed that energy intake was lower during topiramate treatment. Topiramate has been shown to have hypothalamic effects, which could explain the reduction in appetite also recently shown in other clinical trials including diabetic patients. 19, 20 The weight loss seen in the topiramate-treated group can, at least partly, explain the improved blood glucose control in these patients, although the magnitude of improvement seems considerably greater than expected for a 6.6% reduction in body weight. Animal studies indicate that the anti-hyperglycaemic effect of topiramate is independent of its effect on energy intake and/or body weight loss. It has been reported in a pair-fed study that topiramate-treated db/db mice showed a statistically significant reduction in the blood glucose levels, whereas vehicle-treated db/db mice fed the same amount of food as that consumed by topiramatetreated mice, did not.
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The mechanisms underlying the effect of topiramate on the HbA1c reduction as well as FPG levels in these patients are not clear yet. We did not observe a significant improvement in whole-body insulin sensitivity following topiramate treatment although this would have been expected considering the over-all effect on glucose control. However, a similar discrepancy between insulin-stimulated glucose uptake during a clamp and fasting glucose levels has also recently been shown in DM2 patients following 3% reduction in body weight. 22 In preclinical studies, it has been observed that topiramate improved insulin sensitivity in obese diabetic rats. 8 Topiramate showed a marked effect to lower fasting as well as the glucose levels during an oral glucose tolerance test. The glucose clamp studies in these rats showed that topiramate treatment improved insulin sensitivity both at the level of whole-body glucose disposal, as well as the inhibition of hepatic glucose output. The ex vivo study showed that topiramate directly enhanced insulin action in insulin-resistant, but not insulin-sensitive, rat adipose cells suggesting that the in vivo effects of topiramate treatment could be exerted through the adipose tissue. 8 We have also previously found that topiramate increases adiponectin mRNA levels and secretion by murine 3T3-L1 cells in culture. 9 Thus, several studies have shown direct effects of topiramate on rodent and murine adipose cells. However, in contrast, we did not find any direct effects of topiramate on glucose uptake or lipolysis by human fat cells in vitro, including from obese and DM2 subjects. Even after 24 h culture we did not find any effects of topiramate on adiponectin, GLUT-4 or IRS-1 gene expression (data not shown). These results clearly show that human fat cells respond differently to topiramate than rodent and murine adipocytes. 8, 9 In agreement with this, peripheral glucose uptake was not increased in the DM2 patients. Although the hepatic glucose production was further decreased during the clamps in the topiramate-treated patients compared with the placebo-treated group this difference did not reach statistical significance, probably owing to the limited sample size and the relatively high-insulin infusion rate suppressing hepatic glucose production almost completely in both groups.
In addition to insulin resistance, pancreatic islet dysfunction plays a key role in the pathogenesis of DM2. It has been observed that topiramate significantly enhanced glucosestimulated insulin release in DM2 rodent models, accompanied by an increased pancreatic insulin content. 21 In the meal test conducted here, we also observed that the reduced plasma glucose levels were associated with an enhanced insulin/glucose ratio, indicating a trend of increased postprandial insulin release. Even though the plasma free fatty acid (FFA) levels were also significantly lowered during the meal test, the insulin/FFA ratio did not show any clear difference between the groups, again suggesting that the peripheral insulin sensitivity was not different between two groups. Thus, the improved glucose handling during the meal test may be owing to an increased postprandial insulin release, combined with a greater suppression of hepatic glucose output. Further studies exploring the effect of topiramate on glucose-regulated insulin release as well as pancreatic b-cell function are warranted.
In conclusion, we demonstrate that topiramate treatment of overweight DM2 patients results in significant weight reductions and reductions in body fat as well as a marked improvement in the glycaemic control. Interestingly, no improvement in peripheral insulin sensitivity was demonstrated, although we cannot exclude such an effect in the liver. Although frequent side effects were associated with topiramate treatment, limiting its use in obese DM2 patients, novel therapeutic possibilities may emerge from additional studies addressing the mechanisms through which it improves the glycaemic control.
